Zymeworks Inc.
A Vancouver-based biopharmaceutical company that engineers antibody-based cancer therapies. Its Azymetric platform builds bispecific antibodies that can latch onto two targets at once, while its ZymeLink technology attaches chemotherapy drugs to antibodies to deliver them straight to tumors. Founded in 2003, the company's lead drug, zanidatamab, targets HER2-positive cancers.
Granted 278.3K · Sold 132.3K
Granted 17.7K · Sold 6.1K
Granted 54.8K · Sold 29.7K
Granted 37.7K · Sold 19.8K
Granted 459
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Galbraith KennethChair & CEO, Director · 8 transactions | +217.6% | 226.8K | 278.3K | — | 132.3K |
| Hollywood MarkEVP & Chief Operating Officer · 2 transactions | — | 121.4K | 17.7K | — | 6.1K |
| Moore Paul AndrewChief Scientific Officer · 6 transactions | +97.7% | 48.5K | 54.8K | — | 29.7K |
| Smith Jeffrey T LEVP & Chief Medical Officer · 4 transactions | +200.4% | 26.7K | 37.7K | — | 19.8K |
| Patterson Leone DEVP, Chief Bus & Fin Officer · 1 transaction | — | 459 | 459 | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -187.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.